Angel Broking neutral on Cadila Healthcare

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Angel Broking's report on Cadila Healthcare

For 1QFY2016, Cadila Healthcare (Cadila) posted results lower than expected. The company posted sales of `2,378cr (V/s an expected `2,451cr), a yoy growth of 17.7%, driven by exports. Domestic formulations (`742cr) grew by 9.9% yoy, while exports (`1,249cr) grew by 27.9% yoy. On the operating front, the gross margin came in at 64.3% V/s 64.2% expected and V/s 59.7% in 1QFY2015. The OPM came in at 20.1% (V/s 20.5% expected), a yoy expansion of 304bp. The  company posted an Adj net profit of `352cr for the quarter (V/s `372cr expected), a yoy growth of 50.1%. We recommend a Neutral rating on the stock.

Results lower than expected: The company posted sales of `2,378cr for the quarter (V/s `2,451cr expected) a yoy growth of 17.7%, driven by exports. Domestic formulations (`742cr) grew by 9.9% yoy, while exports (`1,249cr) grew by 27.9% yoy. The key export markets to post a robust growth were the US (37.5% yoy growth), and Emerging Markets Formulations (19.5% yoy growth). On the operating front, the gross margins came in 64.3% V/s 64.2% expected and V/s 59.7% in 1QFY2015. The OPM came in at 20.1% (V/s 20.5% expected), a yoy expansion of 304bp. The company posted an Adj. net profit of `352cr (V/s`372cr expected), a yoy growth of 50.1%.

Outlook and valuation: We expect Cadila’s net sales to post an 18.0% CAGR to `11,840cr and EPS to report a 23.0% CAGR to `85.6 over FY2015–17E. We maintain our Neutral rating on the stock, says Angel Broking research report.

For all recommendations, click here 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More